Sally Crawford

Prolacta Bioscience, Inc. provides specialty formulations of human milk for the nutritional needs of premature and critically ill infants. Its products include Prolact+ H2MF, Prolact+4, Prolact+6, Prolact+8, Prolact+10 and Neo20. The company was founded by Elena Taggart Medo in1999 and is headquartered in Duarte, CA.

CombinatoRx, Inc. develops new medicines built from synergistic combinations of approved drugs. The company develops biopharmaceutical products. It conducts clinical trials and research programs. The company was founded by Alexis Borisy, Brent R. Stockwell, Michael A. Foley, Curtis T. Keith and Jacob D. Goldfield in 2000 and is headquartered in Cambridge, MA

Universal American Corp. provides health benefits to people covered by medicare and medicaid. It offers healthcare products and programs, including medicare advantage plans and traditional health insurance. The company was founded on December 22, 2010 and is headquartered in White Plains, NY.

Healthcare Consultants, Inc. specializes in electronic billing and collections. The company is headquartered in Boca Raton, FL.

Part of Simplify Compliance Holdings LLC, Beacon Health Corp. is a private company that provides home health education, policy analysis, publishing, and clinical management services. The company is based in Mequon, WI. Collin Cherry has been the CEO of the company since 2011. Beacon Health was acquired by HCPro, Inc. from NewMarket Latin America on October 01, 2008.

New Hampshire Business Committee for the Arts engages in educate, motivate, and recognize business support of and participation in the arts, advocates for the value of the arts in economic, social and community development, and facilitates people and projects that enhance engagement in the arts. The company was founded in 1985 and is headquartered in Concord, NH.

Part of Elevance Health, Inc., Matthew Thornton Health Plan, Inc. is a private company based in Manchester, NH. Matthew Thornton Health Plan, Inc. was founded in 1971 by Harris Berman.

Zalicus, Inc. is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain. The company develops Z944, a novel oral T-type calcium channel blocker that has completed Phase Ib clinical studies for the treatment of pain indications. It is also engaged in research and preclinical development activities on its selective ion channel modulators targeting the Nav1.7 sodium channel for the treatment of pain. The company changed its name from CombinatoRx, Inc. to Zalicus, Inc. on September 8, 2010. Zalicus was founded on March 28, 2000 and is headquartered in Cambridge, MA.